Citation
Rubio, Marie Thérèse, et al. "Impact of in Vivo T Cell Depletion in HLA-identical Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Conditioned With a Fludarabine Iv-busulfan Myeloablative Regimen: a Report From the EBMT Acute Leukemia Working Party." Journal of Hematology & Oncology, vol. 10, no. 1, 2017, p. 31.
Rubio MT, D'Aveni-Piney M, Labopin M, et al. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017;10(1):31.
Rubio, M. T., D'Aveni-Piney, M., Labopin, M., Hamladji, R. M., Sanz, M. A., Blaise, D., Ozdogu, H., Daguindeau, E., Richard, C., Santarone, S., Irrera, G., Yakoub-Agha, I., Yeshurun, M., Diez-Martin, J. L., Mohty, M., Savani, B. N., & Nagler, A. (2017). Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Journal of Hematology & Oncology, 10(1), 31. https://doi.org/10.1186/s13045-016-0389-4
Rubio MT, et al. Impact of in Vivo T Cell Depletion in HLA-identical Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Conditioned With a Fludarabine Iv-busulfan Myeloablative Regimen: a Report From the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017 01 24;10(1):31. PubMed PMID: 28118857.
TY - JOUR
T1 - Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
AU - Rubio,Marie Thérèse,
AU - D'Aveni-Piney,Maud,
AU - Labopin,Myriam,
AU - Hamladji,Rose-Marie,
AU - Sanz,Miguel A,
AU - Blaise,Didier,
AU - Ozdogu,Hakan,
AU - Daguindeau,Etienne,
AU - Richard,Carlos,
AU - Santarone,Stella,
AU - Irrera,Giuseppe,
AU - Yakoub-Agha,Ibrahim,
AU - Yeshurun,Moshe,
AU - Diez-Martin,Jose L,
AU - Mohty,Mohamad,
AU - Savani,Bipin N,
AU - Nagler,Arnon,
Y1 - 2017/01/24/
PY - 2016/10/04/received
PY - 2016/12/31/accepted
PY - 2017/1/26/entrez
PY - 2017/1/26/pubmed
PY - 2017/11/29/medline
KW - Acute myeloid leukemia
KW - Allogeneic stem cell transplantation
KW - GRFS
KW - Graft-versus-host disease
KW - HLA-matched related donor
KW - In vivo T cell depletion
KW - Relapse incidence
SP - 31
EP - 31
JF - Journal of hematology & oncology
JO - J Hematol Oncol
VL - 10
IS - 1
N2 - BACKGROUND: The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored. METHODS: We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. RESULTS: Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and of its extensive form (8 vs. 26%, p < 0.0001) but similar relapse incidence (22 vs. 27%, p = 0.23) leading to improved GVHD and relapse-free survival (GRFS) (60 vs. 40%, p = 0.0001). In multivariate analyses, the addition of ATG was independently associated with lower chronic GVHD (HR = 0.46, p = 0.0001), improved leukemia-free survival (HR = 0.67, p = 0.027), overall survival (HR = 0.65, p = 0.027), and GRFS (HR = 0.51, p = 4 × 10-5). Recipient age above 50 years was the only other factor associated with worse survivals. CONCLUSIONS: These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.
SN - 1756-8722
UR - https://www.unboundmedicine.com/medline/citation/28118857/Impact_of_in_vivo_T_cell_depletion_in_HLA_identical_allogeneic_stem_cell_transplantation_for_acute_myeloid_leukemia_in_first_complete_remission_conditioned_with_a_fludarabine_iv_busulfan_myeloablative_regimen:_a_report_from_the_EBMT_Acute_Leukemia_Working_Party_
L2 - https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0389-4
DB - PRIME
DP - Unbound Medicine
ER -